eFFECTOR Therapeutics logo

eFFECTOR TherapeuticsNASDAQ: EFTR

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

01 March 2021

Next earnings report:

25 March 2025

Last dividends:

N/A

Next dividends:

N/A
$940.88
-100%vs. 3y high
1%vs. sector
-vs. 3y high
-vs. sector
-100%vs. 3y high
17%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Fri, 22 Nov 2024 16:18:14 GMT
$0.00$0.00(0.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

EFTR Latest News

eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
Zacks Investment Research05 April 2024 Sentiment: NEGATIVE

eFFECTOR Therapeutics (EFTR) plunges on disappointing top-line results from the primary analysis of its mid-stage NSCLC study of tomivosertib, following the abandonment of the developmental program.

Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?
Zacks Investment Research30 January 2024 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 814.5% in eFFECTOR Therapeutics, Inc. (EFTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

3 Top Penny Stocks To Watch Before Next Week
PennyStocks16 November 2023 Sentiment: POSITIVE

Have you ever thought about diving into penny stocks? These are the stocks that won't break the bank, typically trading for less than $5.

Best Penny Stocks To Buy Under $1.25? 3 To Watch Now
PennyStocks24 August 2023 Sentiment: POSITIVE

Are you looking for the best penny stocks to buy? You're not alone; many traders are showing a renewed interest in this exciting market.

Best Penny Stocks To Buy? 5 With Big News This Week
PennyStocks07 June 2023 Sentiment: POSITIVE

Are you searching for some of the best penny stocks to buy now? I'm sure that if you're reading this article, that's something at the top of your mind.

Stock Market Today: New Penny Stocks Trends & 3 To Watch This Week
PennyStocks31 May 2023 Sentiment: POSITIVE

This week has seen the stock market flip-flop, including the volatile world of penny stocks. Investors, especially those interested in high-risk, high-reward low-priced stocks, are attentively tracking the developments in Washington.

Evaluating Market Sentiment With Penny Stocks: Top Tools
PennyStocks29 May 2023 Sentiment: POSITIVE

Penny stocks, known for their low market price and high growth potential, are an exciting segment of the financial market, particularly in sectors like technology. These low-cost shares can provide significant returns if chosen wisely, making it imperative for investors to possess tools and techniques for evaluating market sentiment.

Why Is eFFECTOR Therapeutics (EFTR) Stock Up 75% Today?
InvestorPlace26 May 2023 Sentiment: POSITIVE

EFFECTOR Therapeutics (NASDAQ: EFTR ) stock is taking off on Friday after the company reported positive data from a Phase 2 clinical trial. This includes interim data from its expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib.

eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire28 March 2023 Sentiment: NEUTRAL

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences:

What type of business is eFFECTOR Therapeutics?

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

What sector is eFFECTOR Therapeutics in?

eFFECTOR Therapeutics is in the Healthcare sector

What industry is eFFECTOR Therapeutics in?

eFFECTOR Therapeutics is in the Biotechnology industry

What country is eFFECTOR Therapeutics from?

eFFECTOR Therapeutics is headquartered in United States

When did eFFECTOR Therapeutics go public?

eFFECTOR Therapeutics initial public offering (IPO) was on 01 March 2021

What is eFFECTOR Therapeutics website?

https://effector.com

Is eFFECTOR Therapeutics in the S&P 500?

No, eFFECTOR Therapeutics is not included in the S&P 500 index

Is eFFECTOR Therapeutics in the NASDAQ 100?

No, eFFECTOR Therapeutics is not included in the NASDAQ 100 index

Is eFFECTOR Therapeutics in the Dow Jones?

No, eFFECTOR Therapeutics is not included in the Dow Jones index

When was eFFECTOR Therapeutics the previous earnings report?

No data

When does eFFECTOR Therapeutics earnings report?

The next expected earnings date for eFFECTOR Therapeutics is 25 March 2025